SPN-812
Phase 3Small molecule
Supernus Pharmaceuticals, Inc.SPN-812 is one of 30 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Phase 3.
1
Indications
13
Total Trials
2
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Attention Deficit Hyperactivity Disorder
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Strattera
MMap77
Approved
Vyvanse
TakedaApproved
Revia
TevaApproved
Nicorette
PfizerApproved
Intuniv
PPromius Pharma, LLC
Approved
Rocaltrol
Jazz PharmaceuticalsApproved
Brintellix
TakedaApproved
Buspar
Bristol-Myers SquibbApproved
Northera
LundbeckApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Children3 trials
Adolescent3 trials
Safety and Efficacy2 trials
Attention Deficit Hyperactivity Disorder2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SPN-812. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details